Reperfusion of ischemic myocardium has been postulated to result in a specific oxygen radical-mediated component of tissue injury. In a previous study we demonstrated improved recovery of ventricular function and metabolism when the superoxide radical scavenger superoxide dismutase was administered at the time of postischemic reflow. Studies in vitro, however, have suggested that superoxide toxicity might be mediated via the generation of more reactive hydroxyl radicals in an iron-catalyzed reaction. The present study was designed to test the hypothesis that myocardial reperfusion injury might be reduced by administration of the iron chelator deferoxamine at the time of reflow, most likely by preventing hydroxyl radical formation. Sixteen isolated Langendorff rabbit hearts, perfused within the bore of a superconducting magnet, were subjected to 30 min of normothermic (370 C) total global ischemia followed by 45 min of reperfusion. At reflow eight treated hearts received a 10 ml bolus containing 50 ,mol of deferoxamine followed by an infusion of 1 1 ,.mol/min for the first 15 min of reflow. The hearts were then perfused with standard perfusate for an additional 30 min. Eight untreated control hearts received a similar bolus of perfusate followed by 45 min of standard reperfusion. Serial 5 min 31P nuclear magnetic resonance spectra were recorded. Myocardial phosphocreatine (PCr) content fell to 5% to 7% of control during ischemia in both groups of hearts. Deferoxamine-treated hearts recovered 99 10% of control PCr content, while untreated hearts recovered 60 ± 16%c (p < .05). Intracellular pH fell to 5.9 during ischemia in both groups, before showing more rapid and complete recovery in treated hearts (p < .01). Recovery of developed pressure reached 70 -_t 6% of control in treated hearts compared with 35 + 10% in untreated hearts (p < .05). Iron content of the perfusate was 7 ,M, and by electron paramagnetic resonance spectroscopy was in the form of Fe3+ -EDTA complexes. In the effluent of treated hearts iron was in the form of Fe3+ -deferoxamine chelates. In summary, administration of the iron chelator deferoxamiine at the timie of postischemic reflow results in greater recovery of myocardial function and energy metabolism, which supports the hypothesis that iron plays an important role in the pathogenesis of reperfusion injury Circulation 76, No. 4, 906-915, 1987. OVER THE LAST several years evidence has accumulated to indicate that reperfusion of previously ischemic myocardium, although beneficial, may be accompanied by a specific reperfusion injury. '-4 It has been postulated that oxygen radicals generated during 906 acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro.
postischemic reperfusion are at least in part responsible for this phenomenoni$-6 The free radical hypothesis has been supported by a number of animal studies showing that the administration of the superoxide anion (p°2-) scavenger superoxide dismutase (SOD) during postischemic reperfusion resulted in greater recovery of ventricular functiont1 2, 4. 8 and smaller infarct size. 9 It is also possible that superoxide radicals might exert their membrane-damaging effects indirectly, through the generation of the more reactive hydroxyl radicals (0OH) by the Haber-Weiss reaction '2, 13: O02 + H20 > 02 + OH + OH However, at physiologic pH the rate constant of this reaction is very slow'4 compared with the two-step LABORATORY INVESTIGATION-MYOCARDIAL ISCHEMIA reaction shown below, which is catalyzed by iron. '3 (1) 02-+Fe3---.-->Fe2+ + 02 (2)Fe2+ + H202----->Fe3+ + OH + *OH Ferric iron (Fe3 + ) is first reduced to ferrous iron (Fe2 + ) by reacting with superoxide anion. Fe2+ iron is then reoxidized by hydrogen peroxide (H202), formed by dismutation of .20,15 to generate hydroxyl radical.
This two-step reaction has been termed the superoxidedriven Fenton reaction.
In the present study we tested the hypothesis that administration of the iron chelator deferoxamine at the time of reflow after a period of global ischemia in an isolated buffer perfused rabbit heart would result in improved recovery of myocardial function and energy metabolism, likely by reducing hydroxyl radical formation by this reaction. We chose deferoxamine because it chelates iron with extremely high affinity (Kd = 103 1). 16 Strong chelation would prevent ferric iron from undergoing the cyclic reduction and oxidation required to catalyze hydroxyl radical formation.7 ' 18 The drug is furthermore relatively specific for chelating iron and is currently being used to treat patients with iron-overload states. 16 31P nuclear magnetic resonance (NMR) spectroscopy allowed myocardial energy metabolism to be monitored serially and noninvasively during both ischemia and reperfusion, while allowing simultaneous assessment of ventricular function.4 19 
Methods
Isolated heart preparation. Female New Zealand white rabbits (1.5 to 2.0 kg) were heparinized and anesthetized with intraperitoneal pentobarbital. The hearts were excised, the aorta was cannulated, and retrograde perfusion was initiated within 40 sec. The hearts were then perfused with a modified Krebs-Ringer bicarbonate buffer (pH 7.4) at 370 C at a constant pressure of 80 mm Hg (110 cm H20) within the bore of a superconducting magnet. The buffer contained 1 17mM sodium chloride, 6.0mM potassium chloride, 3.0 mM calcium chloride, 1.0 mM magnesium sulfate, 0.5 mM EDTA, 16.7 mM glucose, and 24 mM sodium bicarbonate. The perfusate was bubbled with a gas mixture of 95% oxygen and 5% carbon dioxide. A sidearm in the perfusion line allowed delivery of boluses of test solutions directly into the heart. Right ventricular pacing at 175 beats/min was achieved by means of a KCl-filled wick electrode connected to a Grass SD-9 stimulator. To assess contractile function a latex balloon was inserted into the left ventricle through the mitral orifice and connected to a Statham P23dB pressure transducer. The balloon was initially inflated with a volume of saline sufficient to produce an end-diastolic pressure of 10 mm Hg, which is on the plateau of the Starling curve for this preparation. All subsequent measurements of developed pressure, calculated as the difference between peak systolic and end-diastolic pressure, were made at this same end-diastolic volume. Left ventricular pressure was recorded on a Brush two-channel direct-writing recorder. Vacuum aspiration of perfusate overflow allowed intermittent measurement of coronary flow.
NMR. 3'P NMR spectra were obtained with a Bruker WH 180 spectrometer at 4.2 tesla. At this field strength phosphorus resonates at 72.89 MHz. The internal diameter of the probe was 25 mm. The instrument was operated in the pulsed Fourier transform mode and interfaced to a Nicolet 1280 computer. Five minute spectra were collected from transients following 45 degree pulses delivered at 2 sec intervals, conditions previously documented to result in minimal spectral saturation. 18 The data   were accumulated with a 2K table at a 3000 Hz spectral width. To quantitate myocardial phosphocreatine (PCr) and ATP content the spectra were plotted and the areas under the individual peaks were measured by graphic integration (Hewlett-Packard graphic tablet integrator). Quantitative data thus obtained are expressed as percent of the preischemic content. The intracellular pH (pHi) was determined from the chemical shift of the inorganic phosphate peak, as previously reported. 20 Electron paramagnetic resonance (EPR) and atomic absorption spectroscopy. EPR spectra were recorded with a VARIAN E-9 spectrometer operating at X-band, as described previously.21 Atomic absorption spectroscopy was performed with a Perkin-Elmer 5000 spectrophotometer. 22 Experimental protocol. After a 20 min equilibration period, baseline functional variables and two 5 min NMR spectra were recorded. Total global ischemia was then induced by crossclamping the perfusion line. Hearts were maintained at 370 C throughout ischemia by superfusion with warm perfusate. During ischemia the intraventricular balloon was deflated and the pacer turned off. Serial 5 min NMR spectra were recorded throughout the ischemic period. After 30 min of ischemia, just before the moment of reflow, eight hearts received a 10 ml bolus of room temperature perfusate containing 50 gmol of deferoxamine, followed by an infusion of 1 1 gmol/min of deferoxamine during the first 15 min of reperfusion. A group of eight control hearts received a 10 ml bolus of standard perfusate followed by standard reperfusion. Pacing was reinstituted at the onset of reflow. After 15 min of reperfusion the balloon was reinflated and perfusion with standard perfusate was continued for 30 additional minutes in both groups of hearts. Serial 5 min NMR spectra were recorded throughout the reperfusion period and developed pressure was measured after 15, 30, and 45 min of reflow.
All hearts received 165 gmol of deferoxamine during the first 15 min of reperfusion. However, since coronary flow varied from heart to heart (mean 27 + 2 ml/min), the drug was delivered at an average concentration of 407 guM (range, 305 to 621 gM). In a separate group of hearts administration of aS mM bolus dose of deferoxamine at room temperature was associated with a transient decrease of developed pressure, which was similar in both duration and magnitude to that observed after intracoronary injection of 10 ml of standard perfusate at the same temperature. Likewise, continuous infusion of 0.5 mM deferoxamine did not cause any change in contractility, in agreement with the findings of Myers et al.23
Chemicals. Deferoxamine mesylate (Desferal, Ciba-Geigy) was supplied as a lyophilized powder and was dissolved in warm oxygenated perfusate before use. All other chemicals were high purity grade reagents purchased from Sigma Chemical Co., St. Louis, MO. Double-distilled, deionized water was used to prepare the perfusate.
Statistical analysis. Data are presented as the mean + 1 SEM. Comparisons between the treated and control groups were made by a two-way analysis of variance (ANOVA) designed for repeated measures.
Results

Metabolic data
PCr content. PCr content decreased rapidly during the early minutes of ischemia, and reached minimum levels preischemic control value (% control), during 30 min of normothermic (370 C) total global ischemia and 45 min of reperfusion. Control measurements were obtained immediately before cross-clamping of the perfusion line (time 0). The arrow points to the time of bolus administration (i.e., just before reflow); the vertical dotted line marks balloon reinflation and the resumption of isovolumetric work as well as the end of the 15 min treatment period. Data are plotted as mean + SEM. Two-way ANOVA showed that the time course of PCr content during reperfusion was significantly different for deferoxamine-treated hearts vs control hearts (p < .05). of 5% to 7% of baseline content at the end of the 30 min ischemic period in both groups (p -NS) (figure 1). Control hearts recovered 55 + 13% of preischemic PCr content within 10 min of reperfusion and 60 + 16% at the end of the 45 min reperfusion period. In contrast, PCr recovery in deferoxamine-treated hearts was almost complete, averaging 99 ± 10% of preischemic content 10 min after reflow and 87 + 8% at the end of reperfusion (p < .05 vs controls by ANOVA). Intracellular pH. The progressive fall in intracellular pH during ischemia was similar in the two groups of hearts (p = NS) (figure 2). By the end of the 30 ischemic period severe myocardial acidosis had developed: pHi reached mean values of 5.9 in both groups. After reflow a gradual rise in pHi was observed in both groups. Deferoxamine-treated hearts regained a normal intracellular pH of 7.09 ± 0.03 within 15 min of reperfusion. In contrast, pHi in control hearts remained acidotic at 6.75 + 0. 1 1 after 15 min ofreperfusion, and likewise remained significantly lower throughout the reperfusion period, reaching only 6.9 + 0.06 after 45 min of reperfusion (p < .01 by ANOVA). ATP content. Myocardial ATP content decreased progressively during the ischemic period, reaching a minimum value of 39% to 45% of control, with a similar time course in the two groups ofhearts (p = NS) (figure 3). After reperfusion ATP content in control hearts remained at end-ischemic levels, averaging 35 ± 6% of baseline at the end of the 45 min reperfusion period. ATP content in treated hearts tended to show some evidence of recovery, reaching 51 + 6% of baseline control by the end of the 45 min reperfusion period. This relatively small difference in ATP content did not, however, reach statistical significance (p = .14 by ANOVA).
Functional data
Developed pressure. Developed pressure measured before the induction of ischemia was 106 ± 6 mm Hg in control hearts and 97 + 5 mm Hg in deferoxaminetreated hearts (p = NS). After 15 min of reperfusion control hearts recovered only 29 + 8% of baseline developed pressure before gradually rising to 10% after 45 min of reperfusion (figure 4). In contrast, deferoxamine-treated hearts recovered 51 ± 6% of baseline developed pressure within 15 min of reflow and 70 + 6% by the end of the 45 min reperfusion period (p < .05 by ANOVA).
End-diastolic pressure. Baseline end-diastolic pressure was also similar (11 ± 1 mm Hg) for both groups of hearts. End-diastolic pressure in control hearts averaged 79 + 12 mm Hg 15 min after reflow and 64 + 9 mm Hg at the end of reperfusion ( figure 5 ). In contrast, for hearts that received deferoxamine at the time of reflow, end-diastolic pressure was only 37 + 5 mm Hg after 15 min of reperfusion and 28 ± 3 mm Hg at the end of reperfusion (p < .005 by ANOVA).
Coronary flow. Coronary flow during the preischemic baseline period was 36 ± 2 ml/min in control hearts and 31 + 2 ml/min in the deferoxamine group (p = NS). Coronary flow (over 1 min) was measured 5, 10, and 14 min after reflow, when the hearts were in a "beating nonworking" condition and receiving deferoxamine or control perfusate. Coronary flow was also measured after 15, 30, and 45 min of reperfusion, when the balloon was reinflated and treatment was no longer being administered. Coronary flow tended to be higher in the deferoxamine group than in control hearts as early as 5 min after reperfusion ( figure 6 ). This difference persisted and became greater after balloon reinflation. At the end of the 45 min reperfusion period coronary flow was 66 ± 6% of baseline in control hearts compared with 78 + 7% in deferoxamine- EPR tubes.24 During perfusion of hearts perfusate was sampled before the aortic cannula, as well as in the effluent from the heart. The Fe3 + EPR spectrum was identical to that of the Fe3 -EDTA standard and the iron concentration was 6.8 0.2 ,M in both the incident solution and the effluent during control perfusion. After postischemic reflow of control untreated hearts the concentration of Fe3 -EDTA in the effluent solution was 7.2 + 0.2 ,uM. The postischemic effluent from deferoxamine-treated hearts exhibited an EPR spectrum at g = 4.3 with line shape identical to that for Fe3 + -deferoxamine and the concentration of Fe3 +deferoxamine was 7.4 0.2 ,M.
Discussion
In the present study administration of the iron chelator deferoxamine at time of reflow, following a period of global ischemia, resulted in greater recovery of myocardial function and energy metabolism than that observed in hearts subjected to standard reperfusion. That the degree of ischemic insult before treatment was the same in both groups of hearts was confirmed by the equal severity of intracellular acidosis and equal falls in ATP and PCr content. Thus, the effect of the treatment must be due to a specific action of the drug on events taking place at or soon after the time of reperfusion. These results are consistent with the hypothesis that a significant degree of myocardial injury occurs during reperfusion, and that this injury is separable from the damage caused by ischemia itself.3-6
Vol. 76, No. 4, October 1987 In our study the hearts treated with deferoxamine showed significantly greater recovery of PCr content and more rapid restoration of a normal intracellular pH compared with untreated control hearts. This difference might be the consequence of better protection of mitochondria and hence, improved rates of aerobic metabolism in deferoxamine-treated myocardium. This metabolic improvement was also accompanied by better preservation of myocardial function. Failure to observe a concomitant improvement in recovery of ATP content is not entirely unexpected. Failure to document significant improvement in recovery of ATP content in the presence of significantly better recovery of PCr content and contractility has been reported previously by other investigators7' 25, 26 and was observed in our recent study of SOD, also administered at the time of postischemic reflow. 4 It has been proposed that significant quantities of oxygen free radicals, particularly superoxide anions, are generated upon reperfusion (i.e., reoxygenation) of previously ischemic myocardium.5 6 Superoxide can be catabolized to hydrogen peroxide through a dismutation reaction catalyzed by endogenous SOD activity. 27 Hydrogen peroxide, which might also be cytotoxic,28 can then be converted to water by tissue catalase or glutathione peroxidase. Several studies have demonstrated a beneficial effect of the combined administration of SOD and catalase in hearts subjected to ischemia and reperfusion, 1-3, 7, 8 thus lending support to the hypothesis that generation of these oxygen metabolites may exert a toxic role during reperfusion. However, improved recovery of postischemic myocardial function and energy metabolism similar in magnitude to that found in the present study was recently documented in our laboratory with the use of the same isolated rabbit heart preparation and treatment with SOD alone begun at the time of reperfusion.4 Combined treatment with SOD and catalase was of no additional benefit.4 A similar result with SOD alone vs combined treatment was reported by Wems et al. 9 for infarct size in an intact canine preparation of acute myocardial infarction.9 These results are consistent with experiments in vitro that have suggested that neither superoxide radicals nor hydrogen peroxide is directly toxic, but that cell injury is related to subsequent generation of the more highly reactive hydroxyl radicals ( OH).12 Likewise, experiments in vivo have demonstrated reduction in reperfusion injury with the hydroxyl radical scavengers mannitol,30 dimethylsulfoxide,31 and dimethylthiourea.32 Thus, it can be hypothesized that a reduction in reperfusion injury can be achieved by any therapy that will scavenge or prevent the formation of hydroxyl radicals. Direct demonstration of free radicals in vivo has been hindered by the very short half-life of these species (microto milliseconds). However, recent EPR studies have documented a rapid rise in the concentration of oxygencentered free radicals within 30 sec of reperfusion in isolated perfused rabbit hearts. 29 The characteristics of this EPR signal are identical to those of an alkyl peroxyl radical (ROO), most likely generated from the reaction of hydroxyl radical with cell membranes or other macromolecules. Peak concentrations of greater than 6.4 ,M have been observed after 15 sec of reperfusion. In a recently performed pilot study the intensity of this oxygen-centered free radical signal was greatly (more than 75%) reduced 15 sec after reperfusion in a heart receiving deferoxamine compared with the signal in a heart receiving standard perfusate ( figure 7) . This finding provides further support for our hypothesis that the beneficial effects of deferoxamine are due to inhibition of hydroxyl radical production and subsequent lipid peroxidation. In interpreting our results, one must allow for the possibility that the beneficial effects of deferoxamine may be related to mechanisms other than iron chelation. The affinity constant of deferoxamine for binding copper is 107 times lower than that for iron, and that for calcium is negligible (Kd 102). 16 Other metals known to be bound by deferoxamine include gallium33 and aluminum.34 Experiments in vitro have suggested that deferoxamine might also act as a direct scavenger 912 3250 3300 3350
MAGNETIC FIELD (Gauss) FIGURE 7. EPR spectra of the oxygen free radical signal, at 77°K (gparalle = 2.033, gpe"ndicular = 2.005), in tissue from Langendorffperfused rabbit hearts freeze clamped after 30 min of ischemia followed by 15 sec of reflow. A, Control reperfusion. B, Reperfusion with deferoxamine administered as a 50 ,.M bolus at the onset of reflow. EPR spectra were obtained and temperature annealed to separate the oxygen radical signal, as described previously.27 of hydroxyl radicals. 35 Concentrations of deferoxamine of less than 1 mM, such as those administered during the first 15 min of reperfusion, did not result in significant free radical scavenging. 35 However, it is possible that the higher concentration contained in the initial 10 ml bolus (5 mM) could have acted, in part, as a direct hydroxyl radical scavenger.
In vivo, hydroxyl radicals are most likely generated from superoxide anions via an iron-catalyzed Fenton reaction. 36 Deferoxamine, an iron chelator produced by bacteria (Streptomices pilosus), has been used as a probe for the study of iron-dependent hydroxyl radical reactions in a variety of systems in vitro12. 137 17, 18 and in vivo.3740 The extremely high affinity constant (Kd 103 ) for ferric iron16 is central to the beneficial effects of deferoxamine. In fact, other lower affinity chelators (such as EDTA or ADP) do not abolish ironcatalyzed hydroxyl radical formation, i8 and might even promote it, due to the transient availability of ferric iron during transitions between bound and unbound states, or by preventing ferric iron from being hydrolyzed under conditions of physiologic pH and oxygen tension. 41 Tighter binding by deferoxamine, on the other hand, makes ferric iron unavailable for such redox reactions. 8 Despite these theoretical considerations, relatively little is known about the role of iron in the pathogenesis of postischemic myocardial reperfusion damage. Beneficial effects of deferoxamine have been shown pre-CIRCULATION A r 1 1 LABORATORY INVESTIGATION-MYOCARDIAL ISCHEMIA viously for brain damage in a preparation of cardiopulmonary resuscitation,3' as well as in isolated hearts exposed to hypoxia and reoxygenation. 38 Recently, deferoxamine pretreatment was shown to reduce the occurrence of reperfusion-induced ventricular fibrillation in isolated rat hearts.39 Improved recovery of cororiary flow after hypothermic ischemia was also reported in hearts treated with deferoxamine, but in the absence of a significant beneficial effect on the recovery of contractility. 23 The pathophysiology of myocardial reflow injury is of special current interest to cardiologists, since reperfusion within the early hours of an acute myocardial infarction is being carried out in increasing numbers of patients. 42, 43 There are several potential sources of iron that could catalyze the Fenton reaction. We measured the concentration of iron derived from contaminants in perfusate reagents and found that the actual iron concentration was 7 gM. This value is similar to that previously reported for buffer-perfused hearts by Myers et al. 38 Using EPR we found that this iron was present in the ferric (Fe3 1) state, as a Fe3 +-EDTA chelate. As previously discussed, chelation by EDTA does not prevent the Fenton reaction. In the presence of deferoxamine we observed that the Fe3 + was chelated by the drug, thus being unavailable to catalyze the Fenton reaction. It is unclear whether protein-bound iron circulating in the blood would be capable of catalyzing the Fenton reaction. Electron paramagnetic resonance studies have demonstrated the ability of iron bound to transferrin to catalyse *OH formation in the presence of superoxide radicals.44 However, these results have subsequently been questioned.45 Another source of iron is the intracellular pool, where iron is principally bound to ferritin. It has been recently shown in vitro that superoxide radicals are capable of releasing iron from ferritin, thereby allowing the formation of hydroxyl radicals 46 Alternatively, the presence of low molecular weight iron chelates has been hypothesized.47 While evidence for the existence of such iron complexes has been presented, definitive identification is lacking. In myocytes the issue is further complicated by the existence of a large pool of iron bound to myoglobin. The ability of this myoglobin-bound iron to catalyze hydroxyl radical generation has also been proposed. 48 If intracellular chelation were required then it would be necessary for deferoxamine to enter cells. Pharmacokinetic studies have shown that the volume of distribution of deferoxamine is larger than the extracellular fluid volume. It has also been shown that the drug concentrates in certain tissues, most notably skeletal muscle,49 and that it is capable of chelating intracellular iron stored in the liver.50 Furthermore, in a recent study in vitro hydroxyl radical-mediated damage was prevented in isolated hepatocytes by pretreatment with deferoxamine followed by washing the cells free of extracellular drug. 12 This result would imply that deferoxamine had entered the cells and chelated intracellular iron.
Alternatively, the beneficial effects of deferoxamine might be due to prevention of hydroxyl radical generation in the extracellular space. We have previously invoked this hypothesis to explain the beneficial effects of macromolecules such as SOD on reperfusion injury.'0 In the absence of leukocytes, oxygen radicals can be generated in the endothelium by the enzyme xanthine oxidase,6 although the presence of this enzyme in rabbit hearts has recently been questioned.5'
Other possible sources of free radicals in the endothelial cells and/or in the vascular space include conversion of prostaglandin G2 to prostaglandin H2 by prostaglandin hydroperoxidase,52 and oxidation of catecholamines released during postischemic reflow. 53 The suggestion that deferoxamine might have acted extracellularly is supported by our observations that peak concentrations of oxygen free radicals are reached within 30 sec and that major differences in metabolic recovery develop within 2 min after reflow.27' 54Thus, although the drug may eventually diffuse intracellularly, it is likely that the dose given at the moment of reflow acted at the vascular level. A reduction in vascular injury is supported by our finding that coronary flow in the treated hearts tended to be higher throughout reperfusion, including time points well after discontinuation of the drug infusion. A similar difference in coronary flow between control and treated hearts was observed in our previous study with h-SOD. 4 The observations that the no-reflow phenomenon actually develops over time during reperfusion55 and that coronary arteries from reperfused hearts exhibit impaired relaxation and increased vasoconstriction56 are consistent with vascular damage, mediated at least in part by free radicals.
In conclusion, our data demonstrate that recovery of myocardial high-energy phosphate metabolism and left ventricular contractility after a period of global ischemia can be greatly enhanced by administration of deferoxamine at the time of and during the early minutes of reperfusion, suggesting that iron-catalyzed hydroxyl radical formation plays a key role in the pathogenesis of reperfusion injury.
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